NUR 600 Module 4 Assignment Draft of Script for PowerPoint Presentation

Sample Answer for NUR 600 Module 4 Assignment Draft of Script for PowerPoint Presentation
NUR 600 Module 4 Assignment Draft of Script for PowerPoint Presentation  
Draft of Script for PowerPoint Presentation 
Slide 1: Introduction 
Greetings everyone. My name is ___, and I welcome you to this presentation on Gabapentin. There are generic and brand versions of gabapentin available. Gabapentin is the generic name for it. Gabapentin is marketed under the brand names Neurontin, Horizant, and Gralise (Pauly et al., 2020).  
Slide 2: Drug Pharmacology 
Gabapentin belongs to a category of drugs known as anticonvulsants. Gabapentin mitigates seizures by reducing aberrant neuronal hyperactivity in the brain. Gabapentin alleviates postherpetic neuralgia (PHN) by modulating the body’s pain perception. The mechanism by which gabapentin effectively treats restless legs syndrome remains unclear. The therapeutic effects of gabapentin primarily target the α2δ-1 subunit of voltage-gated calcium channels. This subunit plays a crucial role in facilitating the movement of pore-forming calcium channels (Pauly et al., 2020).  
Slide 3: Pharmacodynamics  
Gabapentin is an anticonvulsant drug that works by blocking the activity of excitatory neurotransmitters. It is beneficial in treating conditions involving abnormal neurotransmission, such as neuropathic pain and seizure disorders. Although it has a broad therapeutic range, it is not practical in treating absence seizures and has been linked to possibly deadly multi-organ hypersensitivity (Horne et al., 2020). 
Slide 4: Pharmacokinetics 
Gabapentin is a medication absorbed by the intestines via an amino acid transporter known as LAT2. The pharmacokinetics of this substance vary based on the dosage, resulting in reduced bioavailability and delayed peak levels when higher doses are administered. The oral bioavailability of this compound is approximately 80% at a dosage of 100 mg, but it tends to decrease at higher doses (Horne et al., 2020). Gabapentin can penetrate the blood-brain barrier and access the central nervous system. 
Slide 5: Dosing Indications For Use 
Gabapentin is a medication that is prescribed for a range of conditions. The recommended dosage typically begins at 300 mg daily and can be gradually increased to a maximum of 4800 mg (Russo et al., 2022). The effects of this treatment typically show improvement within a week, although it may take up to a month to see significant results. 
Slide 6: Side Effects  
According to Hong et al. (2021), gabapentin may cause severe side effects such as erythema multiforme, anaphylaxis, depression, suicidality, and withdrawal symptoms. Ataxia, lightheadedness, exhaustion, nystagmus, and vomiting are typical side effects. 
Slide 7: Contraindications  
Specific individuals who have a history of allergic reactions, misuse, pregnancy, a sodium/potassium diet, kidney problems, or other health conditions may not be appropriate candidates for gabapentin (Hong et al., 2021). 
Slide 8: Pregnancy Class  
Gabapentin is classified as a pregnancy category B3 drug by AU TGA. This category is assigned to drugs that are used by a limited number of pregnant and childbearing women, with no reported increase in fetal malformation or harmful effects (Evoy et al., 2020). 
Slide 9: Cost Analysis Of The Drug 
The cost of Gabapentin is contingent upon pharmacy, treatment plan, insurance, and formulation. Postherpetic neuralgia and partial seizures are within its approved indications (Evoy et al., 2020). Three-month supplies, mail-order pharmacies, or generic alternatives can help reduce long-term expenses. 
Slide 10: Patient Case Study  
A 59-year-old woman of Caucasian descent, who has a medical background of major depressive disorder and generalized anxiety disorder (GAD), has been admitted to the hospital multiple times due to her condition. She has also experienced thoughts of self-harm and has recently been prescribed gabapentin to help alleviate withdrawal symptoms. 
Slide 11: Patient Education 
Offer comprehensive information to patients about gabapentin, encompassing its advantages, potential adverse effects, and proper administration methods. It is essential to provide information on possible side effects, exercise caution, and emphasize safety measures such as handrails and assistive devices to prevent falls (Evoy et al., 2020). 
Slide 12: Nurse Practitioner Role 
Nursing practitioners prioritize patient care by addressing various aspects of gabapentin treatment, including dosage, schedule, education, safety measures, pain management, and emotional support. They also emphasize the importance of caution, safety measures, and mental health support when necessary (Rissardo et al., 2023). 
Slide 13: Monitoring and Follow-Up 
Monitoring gabapentin treatment requires assessing baseline creatinine levels before and during therapy, providing patients with information, and conducting screenings for depression, behavioral changes, and suicidality (Rissardo et al., 2023). Follow-up for the patient was scheduled in two weeks to monitor treatment outcomes.  
Slide 14: References 
Evoy, K. E., Sadrameli, S., Contreras, J., Covvey, J. R., Peckham, A. M., & Morrison, M. D. (2020). Abuse and misuse of pregabalin and gabapentin: a systematic review update. Drugs, 81(1), 125–156. https://doi.org/10.1007/s40265-020-01432-7 
Hong, J. S. W., Atkinson, L. Z., Al‐Juffali, N., Awad, A., Geddes, J., Tunbridge, E. M., Harrison, P. J., & Cipriani, A. (2021). Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale. Molecular Psychiatry, 27(3), 1339–1349. https://doi.org/10.1038/s41380-021-01386-6 
Horne, A., Vincent, K., Hewitt, C., Middleton, L., Koscielniak, M., Szubert, W., Doust, A., & Daniels, J. (2020). Gabapentin for chronic pelvic pain in women (GaPP2): a multicentre, randomized, double-blind, placebo-controlled trial. Lancet (British Edition), 396(10255), 909–917. https://doi.org/10.1016/s0140-6736(20)31693-7 
Pauly, N., Delcher, C., Slavova, S., Lindahl, E., Talbert, J., & Freeman, P. R. (2020). Trends in gabapentin prescribing in a commercially insured U.S. adult population, 2009-2016. Journal of Managed Care & Specialty Pharmacy, 26(3), 246–252. https://doi.org/10.18553/jmcp.2020.26.3.246 
Rissardo, J. P., De Matos, U. M. A., & Caprara, A. L. F. (2023). Gabapentin-associated movement disorders: a literature review. Medicines, 10(9), 52. https://doi.org/10.3390/medicines10090052 
Russo, M., Graham, B. A., & Santarelli, D. M. (2022). Gabapentin—Friend or foe? Pain Practice (Print), 23(1), 63–69. https://doi.org/10.1111/papr.13165 

Need Help Writing an Essay?

Tell us about your assignment and we will find the best writer for your paper

Write My Essay For Me